Company showcases FDA-cleared ProNephro AKI test as acute kidney injury remains key focus for laboratory medicine professionals.
BioPorto attended the Association for Diagnostics & Laboratory Medicine meeting in Chicago from July 27-31, where acute kidney injury and neutrophil gelatinase-associated lipocalin (NGAL) biomarker testing featured across multiple sessions and exhibits.
The company promoted its US Food and Drug Administration (FDA)-cleared ProNephro AKI (NGAL) test, targeting lab directors, clinical chemistry managers, and medical directors attending the conference. The test is cleared for risk stratification of ICU patients aged 3 months through 21 years for moderate to severe acute kidney injury.
Two dedicated sessions focused on NGAL and AKI applications. The first, “Biomarkers of acute kidney injury in pediatrics: Focus on NGAL,” was presented by Nazim Bithi, PhD, of Baylor College of Medicine/Texas Children’s Hospital. Bithi recently co-authored a validation study for NGAL assays in pediatric populations published in Practical Laboratory Medicine.
The second session, “Thinking beyond creatinine: Next-generation biomarkers for early prediction and diagnosis of acute kidney injury,” was led by Raj Pandya, PhD, DABCC, of University of Utah.
AKI continues gaining attention in laboratory medicine due to recent eGFR calculation changes and the clinical progression from AKI to chronic kidney disease. The ongoing KDIGO project to update AKI guidelines, expected in early 2026, is driving additional interest in biomarker testing approaches.
“ADLM is a gathering of the best collaborators in medicine. Laboratorians provide key information for clinicians and administrators to support decision making along the patient journey,” says Jennifer Zonderman, senior vice president of global marketing and commercialization at BioPorto, in a release. “Our customers and partners are proud to be on the forefront of change for the care of kidneys in patients.”
During the conference, BioPorto met with worldwide distribution partners to discuss current collaborations and review business impact of the FDA-cleared product. The company also discussed its ongoing US study for patients 18 and older with similar ICU indications.
ADLM’s educational programming included a 2024 recorded session featuring Dr Prasad Devarajan on using NGAL biomarkers in acute kidney injury diagnosis, reflecting continued professional interest in alternative approaches to traditional creatinine-based testing.
ID 115670663 © Kowniewping | Dreamstime.com
